Ann: US Patent Office issues Notice of Allowance for NRGBiotic, page-28

So true. At current share price everyone who has bought into MDC is now in the red despite all the success on their cannabis trials. How on earth MXC is worth 3x more than MDC is unbelievable. MDC has delivered in everything they have set out (successful trials) and should be on the end stretch for something big IMO. Don't see why MDC is so vulnerable compared to the rest. But perhaps there is something bigger at play here, like most stocks go through before take off. For a company on home stretch of successful cannabis pain drug it is valued incredibly cheap. 49millionaus$, only 35millionUS$, or 26millionGBP$.... for a company heavy in cannabis pain trials since 2015.... this is bonkers cheap.

Only other comparable cannabis drug would be GW Pharma, bought out for 12billion$.... of which Nanabis is much more effective than.

Also BOT failed acne cream trial is worth more than MDC's successful cancer pain cannabis trial.... something has to give after so many years listed on ASX, compared to all the late comers.

MXC is up 600% since IPO and has delivered nothing and not even at phase2 of their cannabis product.
MDC is down 30% since IPO and is gearing up to Phase3 of a successful cancer pain cannabis trial. Technically MDC should be up 600% too from IPO =$1.20

24c recent raise, and the company is down 40% to 14c since then.

In saying that my DYL holding went as low as this, and is now up near 1$ now.